Inventurus Knowledge Solutions Limited (IKS Health) has entered into a definitive agreement to acquire 100% of TruBridge, Inc. for a bid enterprise value of $557 million. This strategic acquisition unites IKS Health’s care enablement platform with TruBridge’s integrated RCM and EHR capabilities, creating a comprehensive operating system for healthcare. The transaction is expected to be PAT and EPS accretive in FY27, significantly expanding the company’s addressable market and service depth in the U.S. rural hospital sector.
Transaction Overview
IKS Health has proposed to acquire the U.S.-listed TruBridge, Inc. and take the entity private. The transaction carries a bid enterprise value of $557 million, structured with $427 million in equity and $130 million in debt. The acquisition is being funded through approximately $600 million of debt secured for a 5-year term. The initial interest cost is set at SOFR + 275 bps, designed to slide down to 175 bps as leverage ratios decrease over time. The combined entity is expected to maintain a leverage ratio of approximately 3X EBITDA.
Strategic Rationale and Synergy
The acquisition of TruBridge, which serves approximately 1,500 clients with a 3,700-strong workforce, represents a transformative step for IKS Health. By integrating a System of Record (EHR) with a System of Action (Care Enablement Platform), the company aims to eliminate middleware, reduce friction, and provide a single source of truth for clinical and financial data. TruBridge brings a mature, recurring revenue base, with a 6% revenue CAGR and 10% adjusted EBITDA CAGR recorded between 2020 and 2025.
Growth and Market Opportunity
This deal significantly expands IKS Health’s presence in the U.S. rural hospital market, where TruBridge currently serves over 700 clients. Key growth drivers include:
- Revenue Acceleration: Capitalizing on $575 million+ in cross-sell whitespace within the existing TruBridge client base for the IKS Care Enablement Platform.
- Differentiated Technology: Utilizing TruBridge’s suite of proprietary tools, including the TruCode encoder, which addresses a $650 million+ market opportunity.
- Operational Scale: Creating a unified, high-value talent pool of over 17,000 employees, including 2,000+ clinically trained staff and 800+ technologists to drive global delivery excellence.
Financial Outlook
Proforma financials for 2025 indicate a combined revenue of $698 million and an adjusted EBITDA of $186 million. The deal is structured to be PAT and EPS accretive by FY27. Looking ahead, IKS Health has set a vision to reach ₹3,000 crores in EBITDA by FY30, while keeping net debt stable at December 2025 levels. The integration is expected to span 4-5 quarters post-closing, with a focus on unifying organizational structure, leadership, and go-to-market strategies.
Source: BSE
